Susquehanna International Group’s Kazia Therapeutics KZIA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-830
Closed -$16.6K 12549
2024
Q2
$9.46K Buy
+830
New +$12.3K ﹤0.01% 11782
2022
Q2
Sell
-501
Closed -$192K 13470
2022
Q1
$192K Sell
501
-514
-51% -$184K ﹤0.01% 11284
2021
Q4
$429K Buy
1,015
+525
+107% +$262K ﹤0.01% 9577
2021
Q3
$281K Buy
490
+204
+71% +$100K ﹤0.01% 10744
2021
Q2
$141K Sell
286
-200
-41% -$105K ﹤0.01% 11888
2021
Q1
$301K Buy
+486
New +$254K ﹤0.01% 10598
2019
Q1
Sell
-220
Closed -$25K 9394
2018
Q4
$25K Sell
220
-2
-0.9% -$272 ﹤0.01% 8642
2018
Q3
$37K Buy
+222
New +$37.7K ﹤0.01% 8909

Other funds holding KZIA

Susquehanna International Group's KZIA Position: Q3 2024 in Review

Susquehanna International Group sold out of Kazia Therapeutics (KZIA) in Q3 2024, closing a stake of 830 shares — an estimated $16.6K sold.

Susquehanna International Group first reported a position in KZIA in Q3 2018 and held it in 8 quarters. The position peaked at $429K in Q4 2021. 17 funds tracked by Wall St. Rank hold KZIA as of Q3 2024.

  • Susquehanna International Group reported no remaining Kazia Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Susquehanna International Group sold 830 Kazia Therapeutics shares in Q3 2024, an estimated $16.6K.
  • Susquehanna International Group first reported a position in Kazia Therapeutics in Q3 2018 and held it in 8 quarters.
  • Susquehanna International Group's Kazia Therapeutics position peaked at $429K in Q4 2021.
  • 17 funds tracked by Wall St. Rank held Kazia Therapeutics as of Q3 2024.

Based on Susquehanna International Group's 13F filing for Q3 2024, filed 14 Nov 2024.